HealthMore in Health→
Trial Finds Genetic Clue to Which Children May Benefit From a Targeted Cancer Therapy
Researchers in the eSMART trial identified a biomarker linked to response in children with Ewing sarcoma and other hard-to-treat solid tumors, pointing to a more selective use of a PARP inhibitor combination.
Key Takeaways
- Researchers tested a low-dose irinotecan and PARP inhibitor combination.
- Twelve patients benefited across several pediatric tumor types.
DE
DT Editorial Team··via medicalxpress.com